ClinicalTrials.gg
CompletedNCT06070857Updated Dec 16, 2025

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers

A Phase 1 interventional study of LV232 and Placebo in Healthy Subjects, sponsored by Vigonvita Life Sciences. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Vigonvita Life Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study consists of 10 dose groups, 8 subjects in each group (male or female), randomly assigned to study drug or placebo group to evaluate the safety, tolerability and pharmacokinetics characteristics.

Read the detailed description

The dose levels are planned at 1 mg, 2 mg, 4 mg, 8 mg, 15 mg, 25 mg,40 mg, 60 mg ,90 mg and 120mg. 6 subjects in each group will receive LV232 tablets and 2 subjects will receive placebo. The subject number of single dose group may increase or decrease depending on the safety and PK data obtained.1 mg dose group will be given by sentinel administration (i.e. 1 study drug, 1 placebo). Subjects who receive sentinel administration will be observed for 48 hours and investigator will evaluate the safety parameters (including symptoms, vital signs, physical examination, etc.).Based on observed tolerability and safety data or obtained PK data, adjustments are allowed at all dose levels in the clinical trial.

02

Conditions studied

  • Healthy Subjects

Keywords

  • LV232
  • Phase I
  • dose-escalation
  • Tolerability
  • Pharmacokinetic
03

In context

Lead sponsor

Vigonvita Life Sciences is the lead sponsor of 39 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 45 years old, males or females;
  2. Body weight no less than 50.0 kg for male, no less than 45.0 kg for female, of 19.0 to 26.0kg/m2;
  3. Physical examination, vital signs examination, laboratory examination, examination and B-ultrasound examination results were normal or abnormal without clinical significant;
  4. Subjects who are willing to take effective during the study and within 3 months after the study completed;
  5. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study, and signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with to LV232 or any of the ;
  2. Subjects with allergic diseases or allergic constitution;
  3. Subjects with skin diseases or a history of skin allergies;
  4. Subjects with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, Hematologic System, metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials;
  5. Blood donation or blood loss ≥ 400 mL within 3 months , or have a history of blood product use history
  6. Subjects who have participated in clinical trials of other drugs within 3 months before screening;
  7. Subjects who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health products orally within 2 weeks before screening;
  8. Drug or alcohol addicts within 1 year prior to screening, who drink at least twice a day or more than 14 units per week, or who are addicted to alcohol (1 unit ≈200 mL beer with 5% alcohol content, 25 mL spirits with 40% alcohol content or 85 mL wine with 12% alcohol content);
  9. Subjects who smoked more than 10 cigarettes or equivalent amounts of tobacco a day within one year before screening;
  10. Subjects who can't quit smoking and drinking during the experiment;
  11. Subjects who are positive for virus surface antigen, virus antibody, Treponema pallidum antibody (TPPA) or antibody (Anti-HIV);
  12. Abnormal and chest radiographs (anteroposterior);
  13. B ultrasound examination showed moderate to severe fatty liver;
  14. Pregnant or lactating woman or male subjects whose spouse has a child care plan within 3 months;
  15. The investigator believes that there are other factors that are not suitable for participating in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    LV232

    Subjects will receive LV232 orally for single dose.

    Drug: LV232

  • Experimental
    Placebo

    Subjects will receive placebo orally for single dose.

    Drug: Placebo

Interventions

  • DrugLV232

    Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg

  • DrugPlacebo

    Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Incidence of Treatment-Emergent Adverse Events

    Time frame: 7 days after treatment

  2. Cmax

    maximum observed plasma concentration

    Time frame: 48 hours after administration

  3. AUC0-t

    area under the plasma concentration time curve from time zero to the last

    Time frame: 48 hours after administration

  4. AUC0-∞

    area under the plasma concentration time curve from time zero to infinity

    Time frame: 48 hours after administration

  5. AUC0-24h

    area under the plasma concentration time curve from time zero to 24 hours

    Time frame: 48 hours after administration

  6. Tmax

    time at which Cmax occurs

    Time frame: 48 hours after administration

  7. t1/2

    half life of elimination

    Time frame: 48 hours after administration

  8. CL/F

    apparent clearance

    Time frame: 48 hours after administration

  9. Vd/F

    apparent volume of distribution during the terminal phase

    Time frame: 48 hours after administration

  10. Ke

    elimination rate constant

    Time frame: 48 hours after administration

  11. MRT

    mean Resident Time

    Time frame: 48 hours after administration

  12. BP

    Blood Plasma Ratio

    Time frame: 48 hours after administration

  13. BRPP

    binding rate of plasma protein

    Time frame: 48 hours after administration

Secondary outcomes

  1. structural of metabolites

    Structure of main metabolites of LV232 in plasma, feces and urine

    Time frame: From time zero up to 96 hours post-dose following oral administration

  2. Ae

    Cumulative excretion of LV232 and major metabolites in feces and urine

    Time frame: From time zero up to 96 hours post-dose following oral administration

  3. Fe%

    Percentage of LV232 and major metabolites in feces and urine

    Time frame: From time zero up to 96 hours post-dose following oral administration

  4. CLr

    renal clearance rate

    Time frame: From time zero up to 72 hours post-dose following oral administration

  5. Genetic polymorphisms in drug metabolism

    Influence of genetic polymorphisms in drug metabolism enzymes on pharmacokinetics and safety

    Time frame: Before administration

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, Shanghai Municipality 201900, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Nov 2025, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2023
First posted
Oct 6, 2023
StartActual
Oct 5, 2023
Primary completionActual
Nov 17, 2025
CompletionActual
Nov 17, 2025
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06070857
Responsible party
Sponsor
First posted
Oct 6, 2023
Start date
Oct 5, 2023
Primary completion
Nov 17, 2025
Completion
Nov 17, 2025
Last update
Dec 16, 2025

Study contacts

Chen Yu
principal investigator · Shanghai Xuhui Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LV232

Start the discussion